Mobidiag Extends Microbial Diagnostics Platform to Cover Bone and
Joint Infections - Sets New World Record of Detecting 64 Dangerous
Bacteria in a Single Test
Mobidiag announces new record-setting rapid diagnostics product for
bone and joint infections, new microarray-based technology platform
and excellent clinical performance of its herpesviral diagnostics
product
Helsinki, Finland 18 May - the Finnish biotech company Mobidiag
announced today two extensions to its record breaking product family
as well as excellent results from clinical evaluation of its
Prove-it(TM) Herpes rapid diagnostics product. Mobidiag's new
Prove-it(TM) Bone and Joint assay identifies bacteria responsible for
bone and joint infections. The product adds new capabilities to
Mobidiag's microarray platform, which also covers sepsis causing
bacteria. It can now detect a world record of 64 dangerous bacteria
in a single test. Mobidiag's new Prove-it(TM) StripArray platform
enables further extension of assay content and high throughput. The
company also announced excellent clinical evaluation results of its
Prove-it(TM) Herpes microarray assay: the product showed sensitivity
and specificity equaling or surpassing current methods and found
several herpes infections that current tests missed.
"By providing rapid and accurate results, we are redefining
infectious disease diagnostics. The evaluation results demonstrate
the high performance of our Prove-it technology, and with today's
Bone and Joint announcement, our product portfolio now covers a
diagnostics market of over 2 million clinical samples per year in
Europe," said Mobidiag's CEO Jaakko Pellosniemi.
Excellent clinical performance for herpesviral diagnostics product
Mobidiag's Prove-it(TM) Herpes microarray assay achieved excellent
results in an international multicenter evaluation where the product
was compared with current PCR-based methods. Prove-it(TM) Herpes can
identify eight different human herpesviruses simultaneously whereas
current tests commonly search for only one type of virus at a time.
In the evaluation study, Prove-it(TM) Herpes showed clinical
sensitivity of 92 % and specificity of 98 %. In 20 of the 460
examined cerebrospinal fluid (CSF) samples, the test uncovered
pathogens that were not found with the reference methods.
Additionally, the test demonstrated 12 multi-infections which were
missed by current diagnostics. Prove-it(TM) Herpes also identified 15
patients with an HHV7 infection not found by the reference methods.
In hospital use, Mobidiag's test can reduce costs associated with
herpesvirus diagnostics by almost 50 %.
"Due to the wide variety of symptoms, it is difficult to confirm
herpesviral infection based only on clinical examination. Rapid
diagnostics is vitally important as mortality from untreated
encephalitis caused by human herpesviruses can be as high as 50 %.
Prove-it Herpes enables rapid diagnostics of the infection and helps
doctors choose the correct antiviral treatment," Pellosniemi
continued.
Rapid diagnostics for bone and joint infections
Mobidiag also launched the Prove-it(TM) Bone and Joint product for
quick identification of bacteria responsible for bone and joint
infections (BJIs), such as osteomyelitis and septic arthritis. Every
year, more than 150,000 people within the EU are infected with BJIs.
Currently, the diagnosis of BJI's relies on cultures, which are time
consuming and subject to false negative results. Mobidiag's
Prove-it(TM) Bone and Joint identifies bacteria directly from a
clinical sample in only three hours, and enables targeted
antimicrobial treatment to be started quickly. The product adds new
capabilities to Mobidiag's microarray platform, which also covers
sepsis causing bacteria.
Mobidiag's rapid tests help reduce costs in hospitals. For example,
the average time a sepsis patient has to spend in hospital is 12 days
and Mobidiag's test can reduce this time 1-2 days for one fifth of
the patients the with faster and more accurate diagnostics. In a
hospital of 750 beds, this translates to yearly cost savings of over
500 000 euros.
New high throughput technology platform
Mobidiag brings into the market its new Prove-it(TM) StripArray
platform, which enables further extension of assay content and high
throughput. With the platform, up to 96 patient samples can be
analyzed in an automated process. The new platform provides high
reliability, short hands-on time and ease-of-use for the routine
diagnostics users. The protocols in the StripArray platform can be
fully automated enabling the platform to be used in diagnostic
applications requiring high throughput.
Contact:
CEO Jaakko Pellosniemi, Mobidiag Ltd, tel. + 358 40 501 1004,
jaakko.pellosniemi[a]mobidiag.com
Mobidiag Ltd is a Finnish biotechnology company developing, producing
and marketing rapid diagnostic tests to hospital laboratories. The
company focuses on diagnostics of serious infections with DNA-tests.
www.mobidiag.com.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.